Mutational processes that alter large genomic regions occur frequently in developing
tumors. They range from simple copy number gains and losses to the shattering and …

Our understanding of the molecular mechanisms underlying cancer development and
evolution have evolved rapidly over recent years, and the variation from one patient to …

PURPOSE Uterine leiomyosarcoma (uLMS) is an aggressive subtype of soft-tissue sarcoma
with frequent metastatic relapse after curative surgery. Chemotherapy provides limited …

Purpose: Leiomyosarcoma (LMS) is an aggressive sarcoma for which standard
chemotherapies achieve response rates under 30%. There are no effective targeted …

Uterine fibroids (UFs) are the most common benign tumors of female genital diseases,
unlike uterine leiomyosarcoma (LMS), a rare and aggressive uterine cancer. This narrative …

Background Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological
malignancy, with individuals with advanced uLMS having a five-year survival of< 10 …

Uterine leiomyosarcoma (uLMS) is the most common subtype of uterine sarcomas. They
have a poor prognosis with high rates of recurrence and metastasis. The five-year survival …

Uterine inflammatory myofibroblastic tumors (IMTs) are rare mesenchymal neoplasms that
frequently harbor ALK gene rearrangements and have a low risk of metastasis. We reported …

Three main uterine leiomyoma molecular subtypes include tumors with MED12 mutation,
molecular aberrations leading to HMGA2 overexpression, and biallelic loss of FH. These …

Simple Summary Immunotherapy has revolutionized cancer care across different cancer
types. Unfortunately, leiomyosarcoma does not seem sensitive to the first-generation …